{
    "Trade/Device Name(s)": [
        "Revogene",
        "Revogene instrument",
        "Revogene\u00ae"
    ],
    "Submitter Information": "Meridian Bioscience, Inc.",
    "510(k) Number": "K220480",
    "Predicate Device Reference 510(k) Number(s)": [
        "K170558"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OOI"
    ],
    "Summary Letter Date": "February 17, 2022",
    "Summary Letter Received Date": "February 18, 2022",
    "Submission Date": "February 17, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Instrumentation For Clinical Multiplex Test Systems",
        "Instrumentation for clinical multiplex systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "chemistry"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Revogene instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Automated lysis",
        "Automated dilution",
        "Automated amplification",
        "Detection of nucleic acid sequences",
        "Fluorescence-based real-time PCR"
    ],
    "Methodologies": [
        "Real-time PCR",
        "Nucleic acid amplification"
    ],
    "Submission Type(s)": [
        "Instrument",
        "System",
        "Software",
        "Automated system"
    ],
    "Document Summary": "FDA 510(k) summary for Meridian Bioscience Revogene instrument with updated PMT surveillance algorithm software for fluorescence-based real-time PCR detection",
    "Indications for Use Summary": "Revogene instrument is intended for in vitro diagnostic use in performing nucleic acid testing of specific IVD assays in clinical laboratories, with automated sample lysis, dilution, amplification, and fluorescence-based real-time PCR detection of nucleic acids.",
    "fda_folder": "Clinical Chemistry"
}